Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF) (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Depreciation & Amortization (CF) of $407000.0 for Q1 2026, up 70.29% on a YoY basis from $239000.0 in Q1 2025, and up 8.24% sequentially from $376000.0 in Q4 2025.
Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $407000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 70.29% year-over-year to $407000.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 74.67% YoY), and the FY2025 full-year result was $1.3 million, up 54.96% from the prior year.
- Depreciation & Amortization (CF) rose to $407000.0 in Q1 2026, from $376000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $407000.0 in Q1 2026 to a low of $118000.0 in Q4 2024.
- A 5-year average of $266117.6 and a median of $248000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) plunged 52.42% in 2024 and surged 218.64% in 2025, its largest moves.
- Tracing PTGX's Depreciation & Amortization (CF) over 5 years: stood at $256000.0 in 2022, then fell by 3.12% to $248000.0 in 2023, then sank by 52.42% to $118000.0 in 2024, then surged by 218.64% to $376000.0 in 2025, then advanced by 8.24% to $407000.0 in 2026.
- Business Quant data shows PTGX's Depreciation & Amortization (CF) at $407000.0 in Q1 2026, $376000.0 in Q4 2025, and $361000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | 407,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 407,000.00 |
| Mar 31, 2026 | 407,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 361,000.00 |
| Sep 30, 2025 | 361,000.00 |
| Jun 30, 2025 | 304,000.00 |
| Jun 30, 2025 | 304,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | 118,000.00 |
| Dec 31, 2024 | 118,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 236,000.00 |
| Mar 31, 2024 | 236,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Dec 31, 2023 | 248,000.00 |